CN116763827A - 普拉梭菌的应用 - Google Patents
普拉梭菌的应用 Download PDFInfo
- Publication number
- CN116763827A CN116763827A CN202310837466.6A CN202310837466A CN116763827A CN 116763827 A CN116763827 A CN 116763827A CN 202310837466 A CN202310837466 A CN 202310837466A CN 116763827 A CN116763827 A CN 116763827A
- Authority
- CN
- China
- Prior art keywords
- clostridium
- prausnitzii
- heart failure
- praecox
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193403 Clostridium Species 0.000 title claims abstract description 48
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title claims abstract description 9
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 229960004197 prasugrel Drugs 0.000 title claims abstract description 9
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims abstract description 45
- 206010019280 Heart failures Diseases 0.000 claims abstract description 25
- 239000001963 growth medium Substances 0.000 claims abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 claims abstract description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 6
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001632 sodium acetate Substances 0.000 claims abstract description 6
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- 235000015278 beef Nutrition 0.000 claims abstract description 5
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 239000012137 tryptone Substances 0.000 claims abstract description 5
- 239000012138 yeast extract Substances 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000007399 clostridium medium Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- -1 1.0g/L Chemical compound 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229960004249 sodium acetate Drugs 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102400001263 NT-proBNP Human genes 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 description 1
- 229960005077 sodium picosulfate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
普拉梭菌的应用,它属于生物医药技术领域。本发明目的是研究F.prausnitzii对老年心衰的影响。本发明普拉梭菌或包含普拉梭菌的食品、药物用于预防和/或治疗老年心衰的应用。将F.prausnitzii应用梭菌培养基在严格厌氧环境中培养获得改良的F.prausnitzii。所述梭菌培养基的配方成分为胰酪蛋白胨10.0g/L、牛肉浸粉10.0g/L、酵母浸粉3.0g/L、葡萄糖5.0g/L、氯化钠5.0g/L、可溶性淀粉1.0g/L、L‑半胱氨酸盐盐酸0.5g/L、乙酸钠3.0g/L、刃天青0.001g/L,所述梭菌培养基的PH为6.8±0.2。本发明用于老年心衰药物或者食品。
Description
技术领域
本发明属于生物医药技术领域;具体涉及普拉梭菌的应用。
背景技术
普拉梭菌(Faecalibacteriumprausnitzii,F.prausnitzii)是一种革兰氏阳性菌,粪杆菌属,无芽孢、无鞭毛、专性厌氧。它是人类肠道中发现最丰富的肠道微生物之一,占健康人类粪便微生物总数5%。起初F.prausnitzii被归为梭杆菌属,后经研究发现其结构与柔嫩梭菌类群成员更接近,2002年Duncan等建议建立新的菌属Faecalibacterium,并将F.prausnitzii归入该菌属。F.prausnitzii具有维持肠道屏障功能、抗炎等重要作用,有望成为新一代益生菌。
F.prausnitzii是一种高度活跃的功能性肠道细菌,可为结肠细胞提供能量,协同抗炎作用维持肠道健康。F.prausnitzii可发酵葡萄糖,产生丁酸盐、D-乳酸盐和甲酸盐,还可有效利用果糖、淀粉和菊粉等。F.prausnitzii是胃肠道最主要产丁酸的细菌之一,丁酸盐作为结肠细胞主要能量来源,还参与调节免疫反应、抑制癌症进展、保护机体免受病原体侵袭等作用。大量研究证实,F.prausnitzii在炎症性肠病、肠易激综合症、结肠癌、肥胖和糖尿病等多种疾病中具有重要作用。F.prausnitzii相对丰度可作为成人肠道健康的标志物,其丰度减少是IBD的重要特征。
F.prausnitzii在多种疾病中得到越来越广泛的应用。调节肠道菌群已成为治疗和预防肠炎、结直肠癌和神经系统疾病等多种疾病的有效方法。目前,Exeliom公司已开展关于F.prausnitzii治疗克罗恩病患者中安全性和有效性的相关1期试验,克服了F.prausnitzii操作难度的问题,使F.prausnitzii单菌补充成为治疗疾病的潜在手段。F.prausnitzii主要用于治疗炎症性肠病、代谢性疾病的治疗,是否可用于心血管疾病治疗尚无证据。
发明内容
本发明目的是研究F.prausnitzii对老年心衰的影响,提出普拉梭菌的应用。
本发明通过以下技术方案实现:
普拉梭菌或包含普拉梭菌的食品、药物用于预防和/或治疗老年心衰的应用。
进一步的,所述普拉梭菌F.prausnitzii生产厂家为宁波明舟生物科技有限公司,菌种编号为DSM 17677,将F.prausnitzii应用梭菌培养基在严格厌氧环境中培养获得改良的F.prausnitzii。
进一步的,所述梭菌培养基的配方成分为胰酪蛋白胨10.0g/L、牛肉浸粉10.0g/L、酵母浸粉3.0g/L、葡萄糖5.0g/L、氯化钠5.0g/L、可溶性淀粉1.0g/L、L-半胱氨酸盐盐酸0.5g/L、乙酸钠3.0g/L、刃天青0.001g/L,所述梭菌培养基的PH为6.8±0.2。
进一步的,所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。
进一步的,所述食品的剂型为丸剂、胶囊剂、片剂、粉剂、液体剂中的一种。
进一步的,所述药物的剂型为液体剂或固体剂。
进一步的,所述液体剂的活菌浓度为108~1010CFU/ml。
进一步的,所述固体剂的活菌浓度为108~109CFU/g。
本发明的有益效果为:
本发明所述的普拉梭菌的应用,动物F.prausnitzii在老年心衰人群中丰度降低,补充F.prausnitzii可改善老年大鼠心脏功能,提示可作为老年心衰的防治靶点。本发明研究发现了动物F.prausnitzii治疗潜力,具有重大转化意义。
附图说明(图3-图9,最好替换为清晰的图,截图有点模糊)
图1为本发明中F.prausnitzii对老年心衰的影响的技术路线图。
图2为本发明中老年心衰患者粪便F.prausnitzii丰度对比图;
图3为本发明F.prausnitzii对老年心衰的影响的大鼠超声对比图;
图4为本发明F.prausnitzii对老年心衰的影响的射血分数统计对比图;
图5为本发明F.prausnitzii对老年心衰的影响的短轴收缩率统计对比图;
图6为本发明F.prausnitzii对老年心衰的影响的NT-proBNP统计对比图;
图7为本发明F.prausnitzii对老年心衰的影响的心脏大体及HE、Masson染色对比图;
图8为本发明F.prausnitzii对老年心衰的影响的心脏体重比统计对比图;
图9为本发明F.prausnitzii对老年心衰的影响的心室纤维化统计对比图。
具体实施方式
具体实施方式一:
普拉梭菌或包含普拉梭菌的食品、药物用于预防和/或治疗老年心衰的应用。
进一步的,所述普拉梭菌F.prausnitzii生产厂家为宁波明舟生物科技有限公司,菌种编号为DSM 17677,将F.prausnitzii应用梭菌培养基在严格厌氧环境中培养获得改良的F.prausnitzii。
进一步的,所述梭菌培养基的配方成分为胰酪蛋白胨10.0g/L、牛肉浸粉10.0g/L、酵母浸粉3.0g/L、葡萄糖5.0g/L、氯化钠5.0g/L、可溶性淀粉1.0g/L、L-半胱氨酸盐盐酸0.5g/L、乙酸钠3.0g/L、刃天青0.001g/L,所述梭菌培养基的PH为6.8±0.2。
为研究F.prausnitzii对老年心衰的影响,首先,收集老年健康人群及老年心衰人群粪便样本,检测粪便样本中F.prausnitzii丰度。同时,构建老年大鼠粪便粪菌移植模型,模拟老年时肠道菌群改变。随机将成年大鼠分为两组,一组给予对照溶剂,一组给予老年大鼠粪便粪菌移植,一组同时给予老年大鼠粪菌移植和F.prausnitzii灌胃,F.prausnitzii每周3次灌胃。12周后应用小动物超声观察心功能变化;心室病理染色观察心室纤维化;ELISA检测循环NT-proBNP水平,如图1所示。
老年大鼠粪菌移植具体方法为收集老年大鼠粪便样本置于1.5mL EP管。合并的粪便样品在冷冻磷酸盐缓冲液(PBS,120mg粪便/1mL缓冲液)中稀释,并均化5分钟直至达到糊状稠度。将悬浮液涡旋1分钟并以800×g离心3分钟。收集上清液,等分后放置-80℃冰箱中备用。粪菌移植采用灌胃方式,每日一次灌胃,每次约1mL。大鼠第一次粪菌移植需肠道准备,在粪菌移植前3天给予奥美拉唑(50mg/Kg/d)处理,为促进肠道排空在移植前24h和前12h分别给予1mL和2mL的肠道清洁剂(匹可硫酸钠0.16mg/mL和氧化镁51.2mg/mL),完成第一次菌群移植后,每周灌胃一次(无需肠道准备)。
研究应用F.prausnitzii购于宁波明舟生物科技有限公司,菌种编号为DSM17677,研究中F.prausnitzii应用改良强化梭菌培养基在严格厌氧环境中培养获得。
培养基配制方法如下:改良型强化梭菌肉汤培养基(CMC,MB029B)成分如表1所示,分装至15mL离心管进行高温高压灭菌(高压灭菌参数为:0.1Mpa,121℃,15分钟)。开启厌氧工作站,接通氮气、二氧化碳和混合气体(氮气80%、氢气10%、二氧化碳10%),对厌氧工作站进行充分地换气15次,充分排出厌氧工作站中残留的氧气,再放入钯催化剂促进厌氧工作站中的氢气与残留氧气反应,以充分耗竭厌氧工资站中的氧气,保持工作站中严格的厌氧环境。将灭菌处理后的培养基放进厌氧工作站中除24小时,使培养基处于完全无养的状态。
取购买自上海宁波明舟科技有限公司的F.prausnitzii(MSD 17677)甘油菌进行复苏。先取出甘油菌,解冻后将甘油菌全部取出置于10mL培养基中,培养24-72小时。
灌胃菌制备:取6mL处于对数生长期的F.prausnitzii菌液置于50mL离心管中,培养48小时至F.prausnitzii充分生长并且处于生长对数期。提前将甘油高温高压灭菌,高压灭菌参数为:0.1Mpa,121℃,15分钟,将灭菌后的甘油置于厌氧工作站除氧24小时,用PH值为7.3的磷酸盐缓冲液(PBS)将甘油配置成10%。取处于生长对数期的F.prausnitzii进行离心,离心转速为3500rpm,离心时间为10min,弃去上清液,收集菌体,用10mL 10%甘油重悬,使用比浊法对普拉梭菌进行计数,使用10%甘油将普拉梭菌进行稀释,使其终浓度为109CFU/ml,置于-80℃冰箱冻存备用。每周三次灌胃,每次1mL。
表1改良强化梭菌培养基成分
胰酪蛋白胨(Tryptose) | 10.0g/L |
牛肉浸粉(BeefExtract) | 10.0g/L |
酵母浸粉(YeastExtract) | 3.0g/L |
葡萄糖(Dextrose) | 5.0g/L |
氯化钠(NaCL) | 5.0g/L |
可溶性淀粉(SolubleStarch) | 1.0g/L |
L-半胱氨酸盐盐酸(L-CysteineHCL) | 0.5g/L |
乙酸钠(SodiumAcetate) | 3.0g/L |
刃天青(Resazurin) | 0.001g/L |
PH | 6.8±0.2(25℃) |
研究结果:
1.老年心衰患者粪便F.prausnitzii丰度降低
收集住院患者粪便样本,连续入选30例老年健康和30例老年心衰患者,提取患者粪便样本中DNA。qRT-PCR结果如图2所示,与老年健康组相比,老年心衰患者粪便F.prausnitzii丰度明显降低(p<0.01)。qRT-PCR检测各组F.prausnitzii丰度;n=30。
2.补充F.prausnitzii减轻老年菌群失调相关心力衰竭
如图3、图4和图5所示,超声检查发现,与老年粪菌移植组(aged FMT)相比,老年粪菌移植+F.prausnitzii组(aged FMT+F.p)大鼠射血分数和短轴收缩率增加(p<0.05)。
如图6所示,ELISA试剂盒检测发现,与老年粪菌移植组大鼠相比,老年粪菌移植+F.prausnitzii组大鼠血清NT-proBNP水平明显降低(p<0.05)。
如图7、图8和图9所示,与老年粪菌移植组相比,老年粪菌移植+F.prausnitzii组大鼠心脏体重比有降低趋势。HE染色结果显示,老年粪菌移植组大鼠心肌细胞排列紊乱、心肌断裂而老年粪菌移植+F.prausnitzii组大鼠心肌细胞排列较为规整。Masson染色结果显示,与老年粪菌移植组大鼠相比,老年粪菌移植+F.prausnitzii组大鼠心室胶原沉积明显减少,纤维化程度减轻(p<0.05)。这些结果表明,补充F.prausnitzii减轻老年菌群失调相关心力衰竭。
具体实施方式二:
根据具体实施方式一所述的普拉梭菌的应用,所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。
具体实施方式三:
根据具体实施方式一所述的普拉梭菌的应用,所述食品的剂型为丸剂、胶囊剂、片剂、粉剂、液体剂中的一种。
具体实施方式四:
根据具体实施方式一所述的普拉梭菌的应用,所述药物的剂型为液体剂或固体剂。
具体实施方式五:
根据具体实施方式一所述的普拉梭菌的应用,所述液体剂的活菌浓度为108~1010CFU/ml。
具体实施方式六:
根据具体实施方式一所述的普拉梭菌的应用,所述固体剂的活菌浓度为108~109CFU/g。
Claims (8)
1.普拉梭菌或包含普拉梭菌的食品、药物用于预防和/或治疗老年心衰的应用。
2.根据权利要求1所述的普拉梭菌的应用,其特征在于,将F.prausnitzii应用梭菌培养基在严格厌氧环境中培养获得改良的F.prausnitzii。
3.根据权利要求1或2所述的普拉梭菌的应用,其特征在于,所述梭菌培养基的配方成分为胰酪蛋白胨10.0g/L、牛肉浸粉10.0g/L、酵母浸粉3.0g/L、葡萄糖5.0g/L、氯化钠5.0g/L、可溶性淀粉1.0g/L、L-半胱氨酸盐盐酸0.5g/L、乙酸钠3.0g/L、刃天青0.001g/L,所述梭菌培养基的PH为6.8±0.2。
4.根据权利要求3所述的普拉梭菌的应用,其特征在于,所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。
5.根据权利要求4所述的普拉梭菌的应用,其特征在于,所述食品的剂型为丸剂、胶囊剂、片剂、粉剂、液体剂中的一种。
6.根据权利要求5所述的普拉梭菌的应用,其特征在于,所述药物的剂型为液体剂或固体剂。
7.根据权利要求6所述的普拉梭菌的应用,其特征在于,所述液体剂的活菌浓度为108~1010CFU/ml。
8.根据权利要求7所述的普拉梭菌的应用,其特征在于,所述固体剂的活菌浓度为108~109CFU/g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310837466.6A CN116763827A (zh) | 2023-07-10 | 2023-07-10 | 普拉梭菌的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310837466.6A CN116763827A (zh) | 2023-07-10 | 2023-07-10 | 普拉梭菌的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116763827A true CN116763827A (zh) | 2023-09-19 |
Family
ID=87994583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310837466.6A Pending CN116763827A (zh) | 2023-07-10 | 2023-07-10 | 普拉梭菌的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116763827A (zh) |
-
2023
- 2023-07-10 CN CN202310837466.6A patent/CN116763827A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harish et al. | Probiotics in humans–evidence based review | |
JP2018111711A (ja) | リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 | |
KR101349452B1 (ko) | 새로운 락트산간균 균주 및 헬리코박터 필로리에 대한 그사용 | |
JP5400997B2 (ja) | 哺乳動物の大腸内のガス発生及びこれに起因する腹部症状を回避又は低減するための、鉱物質及び場合によっては酢酸生成菌及び/又は酪酸生成菌からなる組成物の使用 | |
US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
KR102656709B1 (ko) | 장 감염과 염증의 치료 및 예방을 위한 조성물 및 방법 | |
WO2020182916A1 (fr) | Bacterie de la famille des christensenellacées dans la prevention et/ou le traitement de maladies inflammatoires chroniques et/ou de maladies gastro-intestinales inflammatoires et/ou de cancers | |
JP6018625B2 (ja) | 高コレステロール血症の処置に使用するためのビフィドバクテリウム属に属する菌株 | |
JP2005508617A (ja) | プロバイオティックビフィドバクテリウム株類 | |
CN108498549B (zh) | 用于改善免疫功能的组合物及其应用 | |
JP7126004B2 (ja) | 組成物及びその使用 | |
WO2005030230A1 (en) | Compositions and methods for treatment or prevention of psoriasis and related disorders | |
CN113322216A (zh) | 一种副干酪乳杆菌b111h及其在代谢综合征中的应用 | |
US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
CA3132239A1 (fr) | Bacterie de la famille des christensenellacees dans la prevention et/ou le traitement de maladies inflammatoires chroniques et/ou de maladies gastro-intestinales inflammatoires et/ou de cancers | |
EP1807097A2 (en) | Peri-operative composition comprising lactobacillus rhamnosus | |
EP3967314A1 (en) | Parabacteroides distasonis strains for use thereof in the treatment and prevention of gastrointestinal diseases and of disorders associated with gastrointestinal diseases | |
KR20120113297A (ko) | 락토바실러스 (Lactobacillus) 균주의 면역조절 성질의 향상 | |
CN116763827A (zh) | 普拉梭菌的应用 | |
WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
KR102617297B1 (ko) | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 | |
WO2019227414A1 (zh) | 一种组合物及其应用 | |
WO2019243563A1 (en) | Non-viable bifidobacterium bifidum bacteria and uses thereof | |
US20070298018A1 (en) | Novel lactobacillus bulgaricus strain and compositions | |
RU2775887C1 (ru) | Способ восстановления собственной кишечной микробиоты после антибиотикотерапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |